The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Molecular genetics of pancreatic intraepithelial neoplasia
Open accessAbstract
Background Recent evidence suggests that noninvasive precursor lesions, classified as pancreatic intraepithelial neoplasia (PanIN), can progress to invasive pancreatic cancer. This review will discuss the major genetic alterations in PanIN lesions.Methods A comprehensive review of the literature was performed in order to find studies on the molecular profile of human PanIN lesions. In addition, recent publications on genetically engineered mouse models of preinvasive neoplasia and pancreatic cancers were reviewed.Results PanINs demonstrate abnormalities at the genomic (DNA), transcriptomic (RNA), and proteomic levels, and there is a progressive accumulation of molecular alterations that accompany the histological progression from low-grade PanIN-1A to high-grade PanIN-3 lesions. Molecular changes in PanINs can be classified as "early" (KRAS2 mutations, telomere shortening, p21(WAF1/CIP1) up-regulation, etc.), "intermediate" (cyclin D1 up-regulation, expression of proliferation antigens, etc.), or "late" (BRCA2 and TP53 mutations, DPC4/SMAD4/MADH4 inactivation, etc.). All the genetic changes observed in PanINs are also found in invasive ductal adenocarcinomas, where they usually occur at a higher frequency. Genetically engineered mice expressing mutant Kras in the pancreas, with or without additional genetic alterations, provide a unique in vivo platform to study the pancreatic cancer progression model.Conclusions Molecular studies have been instrumental in establishing that PanIN lesions are the noninvasive precursors for invasive ductal adenocarcinomas. The availability of molecular date provides the basis for designing rational early detection strategies and therapeutic intervention trials before pancreatic neoplasms invade, with the intention of alleviating the dismal prognosis associated with this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, KRAS mutations are often a founder genetic event involved in the pathogenesis of PDAC and are consistently found in precancerous pancreatic intraepithelial neoplasms”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“however, may be acquired as later events during systemic treatment for metastatic disease and have been found as subclonal genetic alterations in a subset of CRC patients ([25-27])”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citationPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationDPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Self-citationThe multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
Baylin, S. B., & Herman, J. G. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01971-x · Cited by 1,628
PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum
Offield, M. F., Jetton, T. L., Labosky, P. A., Ray, M., Stein, R. W., Magnuson, M. A., Hogan, B. L. M., & Wright, C. V. E. (1996) · Development · doi:10.1242/dev.122.3.983 · Cited by 1,513
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Castillo, C. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,480
The Hedgehog and Wnt signalling pathways in cancer
Taipale, J., & Beachy, P. A. (2001) · Nature · doi:10.1038/35077219 · Cited by 1,393
Research works printed but not linked: 19
- VG Vogel, 2003, Clin Cancer Res, 9, 495S
- AL Cubilla, 1976, Cancer Res, 36, 2690
- DS Klimstra, 1994, Am J Pathol, 145, 1547
- CJ Sherr, 2000, Harvey Lect, 96, 73
- M Schutte, 1997, Cancer Res, 57, 3126
- T Ueki, 2000, Cancer Res, 60, 1835
- MS Redston, 1994, Cancer Res, 54, 3025
- RE Wilentz, 2000, Cancer Res, 60, 2002
- AP Klein, 2001, Cancer J, 7, 266
- GA Griffin, 1995, Cancer Res, 55, 2394
- AV Biankin, 2001, Cancer Res, 61, 8830
- S Gansauge, 1997, Cancer Res, 57, 1634
- ON Tucker, 1999, Cancer Res, 59, 987
- T Vargo-Gogola, 2002, Cancer Res, 62, 5559
- P Argani, 2001, Cancer Res, 61, 4320
- CA Iacobuzio-Donahue, 2003, Cancer Res, 63, 8614
- H Han, 2002, Cancer Res, 62, 2890
- CD Logsdon, 2003, Cancer Res, 63, 2469
- P Argani, 2001, Clin Cancer Res, 7, 3862
Cited by
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
McGuigan, A., Kelly, P., Turkington, R. C., Jones, C., Coleman, H. G., & McCain, R. S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4846 · Cited by 1,908
Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., & Maitra, A. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-3 · Cited by 1,090
“IL-6, IL-8 and TNF-alpha mRNA levels were assessed as described previously [55].”
MethodSelf-citationKopp, J. L., von Figura, G., Mayes, E., Liu, F.-F., Dubois, C. L., Morris, J. P., Pan, F. C., Akiyama, H., Wright, C. V. E., Jensen, K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.025 · Cited by 697
“During disease progression, accumulation of genetic mutations in these lesions leads to an increasing degree of atypia and ultimately PDA (Feldmann et al., 2007).”
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2899 · Cited by 567
“Molecular studies have shown that the PanIN stage correlates with increasing mutation frequency and variet”
Background
Metadata
- Authors
- Feldmann, G., Beaty, R., Hruban, R. H., & Maitra, A.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Journal of Hepato-Biliary-Pancreatic Surgery
- Published
- 2007-05-29
- Volume
- 14
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0944-1166 (ISSN-L)
- 1436-0691
- PMC
- PMC2666331
- OpenAlex
- W2011982648
- Cited by
- 269
- References
- 86
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 7 · 2023: 14 · 2022: 20 · 2021: 29 · 2020: 9 · 2019: 12 · 2018: 16 · 2017: 16 · 2016: 18 · 2015: 15 · 2014: 23 · 2013: 16 · 2012: 16
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Hepato-Biliary-Pancreatic Surgery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA113669)
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK072532)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic intraepithelial neoplasia, pancreatic cancer progression, KRAS mutation, telomere shortening, p21, cyclin D1, BRCA2 mutation, TP53 mutation, genetically engineered mouse models, pancreatic ductal adenocarcinoma, early detection of pancreatic cancer, molecular alterations
- MeSH terms
- Animals, Carcinoma in Situ, DNA, Neoplasm, Humans, Molecular Biology, Mutation, Oncogenes, Pancreatic Neoplasms, Biomarkers, Tumor, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular genetics of pancreatic intraepithelial neoplasia. https://app.cochat.ai/papers/10.1007/s00534-006-1166-5
- The paper
- Feldmann, G., Beaty, R., Hruban, R. H., & Maitra, A. (2007). Molecular genetics of pancreatic intraepithelial neoplasia. Journal of Hepato-Biliary-Pancreatic Surgery. https://doi.org/10.1007/s00534-006-1166-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.